ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every regulatory approval announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
284 announcements with these filters
KRN Heat Exchanger's subsidiary received ₹182.95 Crore investment approval under Rajasthan's RIPS-2024 scheme. This entitles the company to a 1.40% turnover-linked incentive, enhancing Neemrana plant profitability.
Cyber Media (India) Limited received NSE approval to forfeit 1,71,329 partly paid-up equity shares. This follows non-payment obligations related to the company's previous rights issue.
NDL Ventures received no-objection letters from BSE and NSE for its merger with Hinduja Leyland Finance. The approvals are valid for six months for NCLT filing.
Aditya Birla Capital received RBI registration to commence factoring business. This regulatory approval enables the company to expand its financial services portfolio.
Zim Laboratories received Italian regulatory approval for its Dabigatran Etexilate capsules. This authorization facilitates market entry into Italy and potential expansion across Europe.
Lloyds Engineering Works Limited received NOCs from NSE and BSE for its proposed merger scheme. This regulatory milestone enables the company to file the scheme with NCLT.
Lloyds Engineering Works received 'No Objection Certificates' from NSE and BSE for its proposed merger scheme. This key regulatory clearance advances the amalgamation process.
Healthy Life Agritec Limited received the Consent to Operate license for its Bangalore manufacturing unit. Valid until 2035, the license enables commencement of commercial production.
E2E Rail's subsidiary received RDSO prototype testing approval for its Kavach safety system. This qualification step enables participation in upcoming Indian Railway safety technology tenders.
Lupin received tentative U.S. FDA approval for Revefenacin Inhalation Solution, targeting a USD 260.7 million market. This strengthens Lupin's respiratory portfolio in the United States.
FDC Limited received U.S.FDA ANDA approval for Cefixime Oral Suspension USP in two strengths. This regulatory milestone enables the company to market these products in the US.
Lloyds Enterprises received no-objection letters from BSE and NSE for its Composite Scheme of Arrangement. This regulatory milestone allows the company to approach NCLT for final approval.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.
OneSource Specialty Pharma received Karnataka government approval for its Unit II expansion project. The facility expansion enhances manufacturing capacities to service global partners and support growth.